mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2014-3-73-76mrj-564Research ArticleОБЗОРЫREVIEWSМесто препаратов гиалуроновой кислоты в терапии остеоартрозаPlace of hyaluronic acid preparations in therapy for osteoarthrosisБалабановаР. М.BalabanovaR. M.balabanova@irramn.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия 115522, Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115552Russian Federation201422092014837376Copyright © Балабанова Р.М., 20142014Балабанова Р.М.Balabanova R.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/564

Представлены данные о позитивной роли препаратов гиалуроновой кислоты (ГЛК) при лечении остеоартроза (ОА) коленных и тазобедренных суставов. Клинический эффект при внутрисуставном введении препаратов обусловлен их не только люмбрикативным, но и в большей степени противовоспалительным и хондропротективным действием. Длительные курсы ГЛК позволяют замедлить риск эндопротезирования сустава при ОА.

The paper gives data on the positive role of hyaluronic acid (HA) preparations in the treatment of knee and hip osteoarthrosis (OA). The clinical effect of intraarticular agents is not only due to their lumbricative, but also, to a greater degree, anti-inflammatory and chondroprotective activities. The efficacy of HA preparations do not practically depend on their molecular weight. Long-term HA cycles can delay the risk of joint replacement in OA.

остеоартрозгиалуроновая килотагилан G-F 20.osteoarthrosishylan G-F 20.ReferencesЗаболеваемость взрослого населения России в 2013 г. Доступ по ссылке: http://www.rosminzdrav.ru/open/usefull/stat. [Zabolevaemost' vzroslogo naseleniya Rossii v 2013 g. [Incidence of adult population of Russia in 2013]. Available from: http://www.rosminzdrav.ru/open/usefull/stat]Заболеваемость взрослого населения России в 2013 г. Доступ по ссылке: http://www.rosminzdrav.ru/open/usefull/stat. [Zabolevaemost' vzroslogo naseleniya Rossii v 2013 g. [Incidence of adult population of Russia in 2013]. Available from: http://www.rosminzdrav.ru/open/usefull/stat]Эрдес ШФ, Галушко ЕА, Бахтина ЛА и др. Распространенность артралгий и припухания суставов у жителей разных регионов РФ. Научно-практическая ревматология. 2004;(4):42–6. [Erdes ShF, Galushko EA, Bakhtina LA, et al. Joint pain and swelling prevalence in residents of different regions of Russian Federation (preliminary results). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;(4):42–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2004-801.Эрдес ШФ, Галушко ЕА, Бахтина ЛА и др. Распространенность артралгий и припухания суставов у жителей разных регионов РФ. Научно-практическая ревматология. 2004;(4):42–6. [Erdes ShF, Galushko EA, Bakhtina LA, et al. Joint pain and swelling prevalence in residents of different regions of Russian Federation (preliminary results). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;(4):42–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2004-801.Kirwan JR, Elson CJ. Is the progression of osteoarthritis phasic? Evidence and implications. J Rheumatоl. 2000;27(4):834–6.Kirwan JR, Elson CJ. Is the progression of osteoarthritis phasic? Evidence and implications. J Rheumatоl. 2000;27(4):834–6.Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symtoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625–35. DOI: http://dx.doi.org/10.1038/nrrheum.2010.159.Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symtoms of osteoarthritis. Nat Rev Rheumatol. 2010;6(11):625–35. DOI: http://dx.doi.org/10.1038/nrrheum.2010.159.Hochberg MC, Altman RD, April KT, et al. ACR 2012 recommendations for the use of nonfarmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74. DOI: http://dx.doi.org/10.1002/acr.21596.Hochberg MC, Altman RD, April KT, et al. ACR 2012 recommendations for the use of nonfarmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74. DOI: http://dx.doi.org/10.1002/acr.21596.Алексеева ЛИ. Симптоматические препараты замедленного действия при лечении остеоартроза. Consilium medicum. 2009;11(9):100–4. [Alekseeva LI. Symptomatic preparations of the sloweddown action at osteoarthrosis treatment. Consilium medicum. 2009;11(9):100–4. (In Russ.)]Алексеева ЛИ. Симптоматические препараты замедленного действия при лечении остеоартроза. Consilium medicum. 2009;11(9):100–4. [Alekseeva LI. Symptomatic preparations of the sloweddown action at osteoarthrosis treatment. Consilium medicum. 2009;11(9):100–4. (In Russ.)]Dougades M, Nguen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthritis Rheum. 2001;44(11): 2539–47. DOI: http://dx.doi.org/10.1002/1529-131(200111)44:11%3C2539::AIDART434% 3E3.0.CO;2-T.Dougades M, Nguen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthritis Rheum. 2001;44(11): 2539–47. DOI: http://dx.doi.org/10.1002/1529-131(200111)44:11%3C2539::AIDART434% 3E3.0.CO;2-T.Rydell NW, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.VI Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of arthritis in track horses. Acta Vet Scand. 1970;11(2):139–55.Rydell NW, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.VI Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of arthritis in track horses. Acta Vet Scand. 1970;11(2):139–55.Rydell NW, Balazs EA. Effect of of intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and granulation issue formation. Clin Orthop Relat Res. 1971;(80):25–32. DOI: http://dx.doi.org/10.1097/00003086-197110000-00006.Rydell NW, Balazs EA. Effect of of intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and granulation issue formation. Clin Orthop Relat Res. 1971;(80):25–32. DOI: http://dx.doi.org/10.1097/00003086-197110000-00006.Lesley J, Hascall VC, Tammi M, et al. Hyaluronan binding by cell surface CD 44. J Biol Chem. 2000;275(35):26967–75.Lesley J, Hascall VC, Tammi M, et al. Hyaluronan binding by cell surface CD 44. J Biol Chem. 2000;275(35):26967–75.Corrado EM, Peluso GF, Gigliotti S, et al. The effects of intraarticular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evalutions. Eur J Rheum Infl. 1995;(150:47–56. DOI: http://dx.doi.org/10.1679/aohc.61.125.Corrado EM, Peluso GF, Gigliotti S, et al. The effects of intraarticular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evalutions. Eur J Rheum Infl. 1995;(150:47–56. DOI: http://dx.doi.org/10.1679/aohc.61.125.Ghosh P, Read R, Numata Y, et al. The effect of intraarticular administration of hyluronan in a model of early osteoarthritis in sheep. Gait analysis, radiological and morphological studies. Semin Arthritis Reum. 1993;22(6 Suppl 1):18–30. DOI: http://dx.doi.org/10.1016/S0049- 0172(10)80016-2.Ghosh P, Read R, Numata Y, et al. The effect of intraarticular administration of hyluronan in a model of early osteoarthritis in sheep. Gait analysis, radiological and morphological studies. Semin Arthritis Reum. 1993;22(6 Suppl 1):18–30. DOI: http://dx.doi.org/10.1016/S0049- 0172(10)80016-2.Ghosh P, Read R, Numata Y, et al. The effect of intraarticular administration of hyluronan in a model of early osteoarthritis in sheep. Cartilage composition and proteoglycan metabolism. Semin Arthritis Reum. 1993;22(6 Suppl 1):31–42.Ghosh P, Read R, Numata Y, et al. The effect of intraarticular administration of hyluronan in a model of early osteoarthritis in sheep. Cartilage composition and proteoglycan metabolism. Semin Arthritis Reum. 1993;22(6 Suppl 1):31–42.Yoshimi T, Kikuchi T, Obara T, et al. Effectsof high-molecular-weight sodium hyaluronate on experimental osteoarthritis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Relat Res.1994;(298):296–304.Yoshimi T, Kikuchi T, Obara T, et al. Effectsof high-molecular-weight sodium hyaluronate on experimental osteoarthritis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Relat Res.1994;(298):296–304.Shimizu C, Kubo T, Hirasawa Y, et al. Histomorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J Rheum. 1998;25(9):1813–9.Shimizu C, Kubo T, Hirasawa Y, et al. Histomorphometric and biochemical effect of various hyaluronans on early osteoarthritis. J Rheum. 1998;25(9):1813–9.Wobig M, Dickhut A, Maler R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–23. DOI: http://dx.doi.org/10.1016/S0149-2918(98)80052-0.Wobig M, Dickhut A, Maler R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–23. DOI: http://dx.doi.org/10.1016/S0149-2918(98)80052-0.Lindquist U, Tolmachev V, Kairemo K, et al. Elimination of stabilized hyaluronan from the knee joint in healthy men. Clin Pharmacocinet. 2002;41(8):603–13. DOI: http://dx.doi.org/10.2165/00003088-200241080-00004.Lindquist U, Tolmachev V, Kairemo K, et al. Elimination of stabilized hyaluronan from the knee joint in healthy men. Clin Pharmacocinet. 2002;41(8):603–13. DOI: http://dx.doi.org/10.2165/00003088-200241080-00004.Takahashi K, Goomer RS, Harwood F, et al. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3), interleukin-1β (IL-1β), and tissue inhibitor of metalloproteinase- 1(TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage. 1999;7(2):182–90. DOI: http://dx.doi.org/10.1053/joca. 1998.0207.Takahashi K, Goomer RS, Harwood F, et al. The effects of hyaluronan on matrix metalloproteinase-3(MMP-3), interleukin-1β (IL-1β), and tissue inhibitor of metalloproteinase- 1(TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage. 1999;7(2):182–90. DOI: http://dx.doi.org/10.1053/joca. 1998.0207.Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan. Int J Clin Pract. 2002;56(10):804–13.Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan. Int J Clin Pract. 2002;56(10):804–13.Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A metanalysis of randomised controlled trials. J Bone Joint Surg Am. 2004;86-A(3):538–45.Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A metanalysis of randomised controlled trials. J Bone Joint Surg Am. 2004;86-A(3):538–45.Lo GH, LaValley M, McAlindon T, Felson DT. Intraarticular hyaluronic acid in treatment of knee osteoarthritis: A metaanalysis. JAMA. 2003;290(23):3115–21. DOI: http://dx.doi.org/10.1001/jama. 290.23.3115.Lo GH, LaValley M, McAlindon T, Felson DT. Intraarticular hyaluronic acid in treatment of knee osteoarthritis: A metaanalysis. JAMA. 2003;290(23):3115–21. DOI: http://dx.doi.org/10.1001/jama. 290.23.3115.Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Datebase Syst Rev. 2006;(2):CD005321.Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Datebase Syst Rev. 2006;(2):CD005321.Алексеева ЛИ, Шарапова ЕП, Зайцева ЕМ и др. Результаты многоцентрового годичного исследования препарата Дьюралан. Эффективная фармакотерапия. 2011;(37):50–7. [Alekseeva LI, Sharapova EP, Zaitseva EM, et al. Results of multicenter year research of a preparation Dyyuralan. Effektivnaya farmakoterapiya. 2011;(37):50–7. (In Russ.)]Алексеева ЛИ, Шарапова ЕП, Зайцева ЕМ и др. Результаты многоцентрового годичного исследования препарата Дьюралан. Эффективная фармакотерапия. 2011;(37):50–7. [Alekseeva LI, Sharapova EP, Zaitseva EM, et al. Results of multicenter year research of a preparation Dyyuralan. Effektivnaya farmakoterapiya. 2011;(37):50–7. (In Russ.)]Caborn D, Rush J, Lanzer W, et al. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheum. 2004;31:333–43.Caborn D, Rush J, Lanzer W, et al. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheum. 2004;31:333–43.Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis and Cartilage. 2002;10(7):506-517.Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis and Cartilage. 2002;10(7):506-517.Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lowermolecular- weight hyaluronan. Clin Ther. 1999;21(9):549–62. DOI: http://dx.doi.org/10.1016/S0149- 2918(00)80010-7.Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lowermolecular- weight hyaluronan. Clin Ther. 1999;21(9):549–62. DOI: http://dx.doi.org/10.1016/S0149- 2918(00)80010-7.Pritchard CH, Sripada P, Bankes P, et al. A retrospective comparison of the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J Musculoskelet Res. 2002;(6):197–205. DOI: http://dx.doi.org/10. 1142/S021895770200085X.Pritchard CH, Sripada P, Bankes P, et al. A retrospective comparison of the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J Musculoskelet Res. 2002;(6):197–205. DOI: http://dx.doi.org/10. 1142/S021895770200085X.Raman R, Duta A, Day N, et al. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatmen of osteoarthritis of the knee – a prospective randomized clinical trial. Knee. 2008;15(4):318–24. DOI: http://dx.doi.org/10.1016/j.knee.2008.02.012.Raman R, Duta A, Day N, et al. Efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatmen of osteoarthritis of the knee – a prospective randomized clinical trial. Knee. 2008;15(4):318–24. DOI: http://dx.doi.org/10.1016/j.knee.2008.02.012.Caborn D, Rush JL, Lanzer W, et al. A randomised singl blind comparison of the of the efficacy and tolerability of Hylan G-F 20 and triamcinolone hexaacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333–43.Caborn D, Rush JL, Lanzer W, et al. A randomised singl blind comparison of the of the efficacy and tolerability of Hylan G-F 20 and triamcinolone hexaacetonide in patients with osteoarthritis of the knee. J Rheumatol. 2004;31(2):333–43.Jubb RW, Piva S, Beinat L, et al. A oneyear, randomised, placebo(saline) controlled trial of 530-700 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57(6):467–74.Jubb RW, Piva S, Beinat L, et al. A oneyear, randomised, placebo(saline) controlled trial of 530-700 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract. 2003;57(6):467–74.Wang Y, Hall S, Hanna F. Effect of hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMS Muskuloskelet Disord. 2011;(12):195–203. DOI: http://dx.doi.org/10.1186/1471-2474-12-195.Wang Y, Hall S, Hanna F. Effect of hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMS Muskuloskelet Disord. 2011;(12):195–203. DOI: http://dx.doi.org/10.1186/1471-2474-12-195.Goldberg VM, Coutts RD. Pseudoseptic reaction to hylan viscosupplementation: diagnosis and treatment. Clin Orthop. 2004;(419):130–7. DOI: http://dx.doi.org/10.1097/00003086- 200402000-00021.Goldberg VM, Coutts RD. Pseudoseptic reaction to hylan viscosupplementation: diagnosis and treatment. Clin Orthop. 2004;(419):130–7. DOI: http://dx.doi.org/10.1097/00003086- 200402000-00021.Migliori A, Bizzi E, Massafra U, et al. The impact of treatment with Hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip osteoarthritis: a retrospective study. Curr Med Res Opinion. 2012;28(5):755–60. DOI: http://dx.doi.org/ 10.1185/03007995.2011.645563.Migliori A, Bizzi E, Massafra U, et al. The impact of treatment with Hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip osteoarthritis: a retrospective study. Curr Med Res Opinion. 2012;28(5):755–60. DOI: http://dx.doi.org/ 10.1185/03007995.2011.645563.

The authors declare that there are no conflicts of interest present.